Docetaxel News and Research

RSS
Docetaxel is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of breast and non-small cell lung cancer (NSCLC). It is also approved to be used with other drugs to treat squamous cell carcinoma of the head and neck (SCCHN) and certain types of gastric and prostate cancer.

Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent.
European approval for Taxotere (docetaxel) in prostate cancer

European approval for Taxotere (docetaxel) in prostate cancer

Genetic predictions may bring “quantum leap” in breast cancer treatment success

Genetic predictions may bring “quantum leap” in breast cancer treatment success

Prostate cancer patients who no longer respond to hormone therapy may benefit from a combination of docetaxel and estramustine

Prostate cancer patients who no longer respond to hormone therapy may benefit from a combination of docetaxel and estramustine

Men with advanced, incurable prostate cancer can benefit from docetaxel

Men with advanced, incurable prostate cancer can benefit from docetaxel

Breast cancer drug Taxotere extends life of prostate cancer patients

Breast cancer drug Taxotere extends life of prostate cancer patients

More women are surviving advanced breast cancer

More women are surviving advanced breast cancer

New screening technique to look for genes that change patients' responses to cancer drugs and other medications

New screening technique to look for genes that change patients' responses to cancer drugs and other medications

Alimta receives positive endorsement for lung cancer approval from FDA Advisory Committee

Alimta receives positive endorsement for lung cancer approval from FDA Advisory Committee

European Commission has approved the use of Herceptin® (trastuzumab) in combination with Taxotere®

European Commission has approved the use of Herceptin® (trastuzumab) in combination with Taxotere®

Investigational drug Abraxane is active and well tolerated in women with metastatic breast cancer

Investigational drug Abraxane is active and well tolerated in women with metastatic breast cancer

Docetaxel decreases the chance of dying by 24 percent in advanced-stage prostate cancer patients resistant to hormone therapy

Docetaxel decreases the chance of dying by 24 percent in advanced-stage prostate cancer patients resistant to hormone therapy

First drug approved for hormone refractory prostate cancer that has shown a survival benefit

First drug approved for hormone refractory prostate cancer that has shown a survival benefit